Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molnupiravir for post-exposure prevention of COVID-19 in household contacts
jRCT2031210281Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Molnupiravir with Placebo (2 arms). Primary endpoints: Development of COVID-19 through Day 14 in baseline SARS-CoV-2-negative participants, Participants with at least 1 adverse event and 1 more. Started Jan 2022; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210281.